BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

(marketscreener.com) Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expressionhttps://www.marketscreener.com/quote/stock/BEIGENE-LTD-26123632/news/BeiGene-Presents-New-Research-from-Tislelizumab-Global-Development-Program-at-2023-ASCO-Gastrointest-42753086/?utm_medium=RSS&utm_content=20230117